TargED Biopharmaceuticals
Founded 2018 · 40 employees on LinkedIn · 8 known investors
TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis. Its lead compound, TGD001, is a targeted thrombolytic in preclinical development for thrombotic disorders including immune thrombotic thrombocytopenic purpura (iTTP) and acute ischemic stroke.
Investors · 8
Frequently asked questions
- What does TargED Biopharmaceuticals do?
- TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis. Its lead compound, TGD001, is a targeted thrombolytic in preclinical development for thrombotic disorders including immune thrombotic thrombocytopenic purpura (iTTP) and acute ischemic stroke.
- Who are TargED Biopharmaceuticals's investors?
- TargED Biopharmaceuticals's investors include Andera Partners, Curie Capital, Fund+, Hadean Ventures, Rotrip, BioGeneration Ventures, Inkef, Sunstone Capital.